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Abstract
Histone deacetylase (HDAC) inhibitors arrest cancer cell growth and cause apoptosis with low toxicity thereby constituting a
promising treatment for cancer. In this study, we investigated the anti-tumor activity in lung cancer cells of the novel cyclic
amide-bearing hydroxamic acid based HDAC inhibitors SL142 and SL325. In A549 and H441 lung cancer cells both SL142
and SL325 induced more cell growth inhibition and cell death than the hydroxamic acid-based HDAC inhibitor
suberoylanilide hydroxamic acid (SAHA). Moreover, the combination treatment using retinoid drugs ATRA or 9-cis RA along
with SL142 or SL325 significantly induced more apoptosis and suppressed colony formation than the single use of either.
The expression of the retinoic acid receptors RARa, RARb, RXRa and RXRb were unchanged with the treatment. However a
luciferase reporter construct (pGL4. RARE 7x) containing seven tandem repeats of the retinoic acid responsible element
(RARE) generated significant transcriptional activity after the combination treatment of retinoic acids and SL142 or SL325 in
H441 lung cancer cells. Moreover, apoptosis-promoting Bax expression and caspase-3 activity was increased after the
combination treatment. These results suggest that the combination treatment of SL142 or SL325 with retinoic acids exerts
significant anti-tumor activity and is a promising therapeutic candidate to treat human lung cancer.
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Introduction
Histone deacetylase (HDAC) and histone acetyltransferase
(HAT) are involved in the co-regulation of chromatin remodeling
and the functional regulation of gene transcription [1]. HDACs
regulate various kinds of biological processes, including prolifer-
ation, differentiation, and apoptosis [2]. There are several reports
that altered HAT or HDAC activity is associated with various
cancers [3,4,5,6]. A number of small-molecule HDAC inhibitors
have been developed as anti-cancer agents. In fact, HDAC
inhibitors were shown to induce cell cycle arrest, differentiation
and apoptosis in a variety of malignant cells. HDAC inhibitors
increase acetylation of histones and transcription factors, which
can reverse gene silencing thus facilitating gene expression [7].
These effects are mediated in part by selective alteration in gene
expression, such as the induction of p21waf expression [8].
However, not all genes are up-regulated by treatment with HDAC
inhibitors, and the ratio of up-regulated to down-regulated genes
has been found to be close to 1:1 [9].
Lung cancer is the leading cause of death worldwide [7]. The
two main forms of lung cancer are non–small cell lung cancer
(NSCLC) and small cell lung cancer (SCLC). Treatment outcomes
for advanced NSCLC using chemotherapeutic agents have been
disappointing. Clearly, further investigation is urgently needed for
the treatment of advanced NSCLC. New treatments with novel
mechanisms of action, including agents that target angiogenesis
and the regulation of gene expression by retinoic acids have been
explored [10,11,12,13]. Without ligand, retinoic acids receptors
act as transcriptional repressors due to the binding of corepressor
complexes that contain histone deacetylases (HDAC). Ligand
binding releases these co-repressors and recruits co-activator
complexes, which could generate histone acetylase activity
[13,14]. It has been reported that the combinations of all-trans
retinoic acid and HDAC inhibitors have an anti-tumor effect
[15,16]. The combination of all-trans retinoic acid (ATRA) and
some HDAC inhibitors showed an anti-tumor effect in neuro-
blastoma [15,16]. The combination therapy of retinoic acids with
HDAC inhibitors may improve efficacy while reducing side effects
The purpose of the present study is to develop a new strategy to
treat lung cancer. We have therefore analyzed the effect of using
the combination of novel, class selective cyclic amide-bearing
hydroxamic acid based HDAC inhibitors SL142 or SL325 [17]
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13834combined with retinoic acids to test their efficacy for treating lung
cancer.
Materials and Methods
Reagents
SL-142 ((E)-3-(2-(4-pyridin-4-yl)benzyl-1-oxoisoindolin-6-yl)-N-
hydroxyacrylamide) and SL-325 ((E)-3-(2-(4-quinolin-3-yl)benzyl-
1-oxoisoindolin-6-yl)-N-hydroxy-acrylamide) are novel isoindoli-
none-hydroxamicacid based histone deacetylase(HDAC)inhibitors
derived from our structural development studies of the multi-drug
template thalidomide for the creation of structurally novel drugs
(Fig. 1A)[18,19].
Cell Lines and Culture Conditions
The human non-small cell lung cancer cells A549, H441 and
H1299 were obtained from the American Type Culture Collection
(Manassas, VA) and grown in Ham’s F12 (A549 cells), RPMI 1640
(H1299 cells) with high glucose Dulbecco’s modified Eagle
medium supplemented with 10% heat-inactivated fetal bovine
Figure 1. SL142 and SL325 significantly suppressed cell viability in H441 and A549 lung cancer cells. A. Chemical structure of SAHA,
SL142 and SL325. B. Detection of H4 acetylation by immunoblot 24 hours after SAHA, SL142 or SL325 treatment (0.5 or 2.0 mM) in H441 lung cancer
cells. b-actin is shown as control. C. Effect on cell viability induced by SAHA, SL142 or SL325. Cells were plated in 96-well plates at a density of 1610
3
cells/well 24 hours prior to treatment with SAHA, SL142 or SL325 (0.1 to 10 mM). Cell viability was evaluated at 96 hours following treatment by the
WST1 assay (Roche, Basel, Switzerland) according to the manufacturer’s protocol. **, significant difference from the cell viability treated with 0.1 mM
of SAHA, SL142 or SL325 (p,0.01).
doi:10.1371/journal.pone.0013834.g001
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lysates of human adult lung tissue were obtained from Novas
Biologicals (Littleton, CO).
Immunoblot analysis
Cellswerelysedinicecold lysisbuffer[1%TritonX-100,20 mM
Tris-HCL (pH 8.0), 137 mM NaCl, 10% glycerol (v/v), 2 mM
EDTA, 1 mM sodium orthovanadate (v/v) 1 mM phenylmethyl-
sulfonyl fluoride]. Cell lysates were clarified by centrifugation
(10 min at 15,0006 ga t4 uC) and protein concentration was
determined using the DC protein assay (BioRad, Hercules, CA).
Equal amounts of protein were separated on an SDS-PAGE gel.
The gel was electrophoretically transferred to a Hybond PVDF
transfer membrane (Amersham, Arlington Heights, IL). The
membrane was incubated with primary and secondary antibodies
according to the Supersignal
R West Pico chemiluminescence
protocol (Pierce, Rockford, IL) to detect secondary antibody
binding. Antibody specific for b-actin antibody was obtained from
Sigma (St. Louis, MO) and antibody specific for human RARa and
RXRa were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti- RARb, RXRb and Histone H4 acetyl antibody were
obtained from Abcam (Cambridge, UK). Antibody specific for
human Bax, p21 and p27 were obtained from Cell Signaling
Technology (Danvers, MA). Secondary horseradish peroxidase-
conjugated antibodies were obtained from Jackson Immunore-
search Laboratories (West Grove, PA).
Inhibition and measurement of caspase activity
Caspase-3 activity was determined using ApoAlert caspase
colorimetric assay kits obtained from Clontech (Mountain View,
CA) according to the manufacturer protocol. The fold increase in
the activity was determined by comparing the levels of caspase
activity in treated cells with those in control cells (DMSO). For
caspase inhibition, cells were incubated with 100 mM zVAD-fmk
obtained from BioVision (Mountain View, CA).
Flow cytometric analysis for apoptosis
Cells were plated in 24-well plates at a density of 0.5–1.0610
5
cells per well 1 day before the treatments. After 72 or 96 hours,
cells were harvested and washed once with PBS. Cells were
resuspended in PBS containing 0.2% Triton X-100 and 1mg/ml
RNase for 5 min at room temperature and then stained with
propidium iodide at 50 mg/ml to determine sub-G0/G1 DNA
content using a FACScan. Doublets, cell debris, and fixation
artifacts were gated out, and sub-G0/G1 DNA content was
determined using Cell Quest Ver. 3.3 software.
Clonogenic survival
H441 cells were first plated at a density of 2610
5 cells per well
in six-well plates 24 hr before treatment. After treatment with
HDAC inhibitors (0.5 mM) and/or retinoic acids (2.5 mM) for
36 hours, cells were released from the dish by incubation with
trypsin/EDTA, counted, and plated in triplicate at a density of
2610
3 cells in 100-mm dishes for 16 days. The cells were then
fixed with 100% methanol and allowed to air dry. The cells were
stained with 0.1% crystal violet. Colonies (groups of aggregated
cells numbering at least 50) were then counted. The mean number
of the PBS treated cells was arbitrarily set to 100%, and all other
numbers were normalized accordingly.
Plasmids and Transient transfection reporter assays
Double stranded DNA containing seven repeats of the RARE
sequence [20,21] was synthesized and ligated into the NheI and
HindIII sites of the pGL.4.24 luciferase reporter construct (pGL4.
RARE 7x; Promega, Madison, WI). The luciferase reporter
construct pGL4 Bax was generated by subcloning the promoter
region of Bax 21570/+68 from genomic DNA using PCR
primers: 59-tttctcgag
XhoIgaagtccaagagatcttcctgacaccctagtctga and
59- tttaagctt
HindIII caccgccgctcccgccgccgcctctcgccgggtcc. The
PCR-generated fragment was digested with XhoI and HindIII
and subcloned directly into the pGL.4.24 - luciferase reporter
construct (Promega). All transfections were carried out in six-well
plates. H441 lung cells were seeded 24 hours prior to transfection
at a density of 0.3610
6/well. Transfections were carried out with
Lipofectin (Invitrogen Life Technologies, Carlsbad, California,
USA) in accordance with the manufacture’s protocol. H441 lung
cells were seeded 24 hours prior to transfection at a density of
0.36106/well. Transfections were carried out with Lipofectin
(Invitrogen Life Technologies, Carlsbad, California, USA) in
accordance with the manufacture’s protocol. 4 hours after
transfection, cells were treated with HDAC inhibitors and/or
retinoic acids. 24 hours after HDAC inhibitors and/or retinoic
acids treatment, cells were harvested. The results of one
representative experiment are presented as fold induction of
relative light units normalized to b-galactosidase activity relative to
that observed for the control vectors. Each experiment was
repeated at least three times. Error bars indicate the standard
deviation from the average of the triplicate samples in one
experiment.
Statistical analysis
Statistically significant differences between means and medians
of studied groups were evaluated using Student’s t-test or the non-
parametric Mann-Whitney U-test. An analysis of variance
(ANOVA) test, where appropriate, was used to identify statistical
significance for multiple comparisons. Statistical significance was
defined as p,0.05 (*, #), p,0.01 (**).
Results
Effects of SL142 and SL325 on H4 acetylation
To analyze the histone deacetylase activity of SL142 and
SL325, immunoblot analysis was performed. Incubation of H441
cells for 24 hours with SAHA, SL142 and SL325 caused a dose-
dependent increase in histone H4 acetylation. Both SL142 and
SL325 demonstrated stronger H4 acetylation than SAHA at
concentrations of 0.5 mM and 2.0 mM. SL142 caused a much
greater increase in histone H4 acetylation than SL325 at a
concentration of 2.0 mM (Fig. 1B). These results demonstrate that
both SL142 and SL325 increase histone H4 acetylation more than
SAHA [22] in H441 lung cancer cells.
SL142 and SL325 significantly suppressed cell viability in
H441 and A549 lung cancer cells
In order to analyze the anti-tumor effect of HDAC inhibitors,
we measured cell viability by the MTS assay after treatment with
SAHA, SL142 and SL325 in H441, A549 and H1299 lung cancer
cells. The cell viability assay revealed that all the HDAC inhibitors
(SAHA, SL142 and SL325) strongly suppressed cell viability of
H441, A549 and H1299 lung cancer cells at a concentration of
10 mM. In lower concentrations (0.5–5.0 mM), both SL142 and
SL325 significantly suppressed the cell viability of H441 and A549
lung cancer cells (Fig. 1C). These results suggest that SL142 and
SL325 are more effective in suppressing the cell viability of
H441 and A549 lung cancer cells than SAHA and at lower
concentrations.
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activity induced apoptosis in H441 and A549 lung cancer
cells
We analyzed caspase-3 activity and apoptosis in H441, A549
and H1299 lung cancer cells after treatment with HDAC
inhibitors. SAHA, SL142 and SL325 increased caspase-3 activity
in all cell types. Significantly, SL142 and SL325 induced higher
caspase-3 activity (2.25– to 2.48 fold) than SAHA (1.42– to 1.66
fold) in H441 and A549 lung cancer cells (Fig. 2A). Next we
investigated apoptosis induced by HDAC inhibitors in lung cancer
cells. As shown in Fig. 2B, SL142 and SL325 induced more sub-
G0/G1 DNA content (51.36–55.81% and 35.07–43.80% respec-
tively) than SAHA (10.47–12.12%) in H441 and A549 lung cancer
cells after a 72 hour treatment. However, these HDAC inhibitors
induced less apoptosis in H1299 lung cancer cells. These results
suggest that SL142 and SL325 more effectively increase caspase-3
Figure 2. SL142 and SL325 suppressed cell growth and induced apoptosis in H441 and A549 lung cancer cells. A. Analysis of caspase-3
activity in A549, H441 and H1299 lung cancer cells after SAHA, SL142 and SL325 treatment. Cells were treated with SAHA, SL142 or SL325 at a
concentration of 2.5 mM for 36 hours. Triplicate experiments were performed; data represent the mean-fold increase 6 S.E. Significant difference
from cells treated with PBS and cells treated with HDAC inhibitors indicated was shown (*p,0.05, **,0.01). B. Flow cytometric analysis of apoptosis
induced by SAHA, SL142 or SL325. Cells were infected with SAHA, SL142 or SL325 at the concentration of 2.5 mM for 72 hours and sub-G0/G1 DNA
content was measured by propidium iodide staining and flow cytometric analysis.
doi:10.1371/journal.pone.0013834.g002
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cells than SAHA.
ATRA or 9-cis RA enhanced caspase-3 activity induced by
SL142 or SL325 and increased apoptosis in H441
pulmonary adenocarcinoma cells
To analyze the combination effect of retinoic acids with SL142
or SL325, we examined the caspase-3 activity and sub-G0/G1
DNA content using propidium iodide staining with flow cytometry
and caspase-3 activity after single or combination treatment. As
shown in Fig. 3A, both ATRA and 9-cis RA induced no caspase-3
activity while a single treatment of SAHA, SL142 or SL325
significantly increased caspase-3 activity (1.38– to 2.13-fold) in
H441 pulmonary adenocarcinoma cells. Importantly, retinoic acid
enhanced caspase-3 activity induced by SAHA, SL142 or SL325
and the combination of ATRA or 9-cis RA, and SL142 or SL325
increased caspase-3 activity (2.47– to 2.91-fold) more than ATRA
or 9-cis RA and SAHA alone (1.90– to 2.04-fold). 100 mMo f
zVAD-fmk effectively inhibited the caspase-3 activity in all the
experiments. Next, we investigated the amount of apoptosis
induced by the HDAC inhibitors in lung cancer cells. Sub-G0/G1
DNA content was increased to 5.98% to 8.58% after a single
treatment of retinoic acids or HDAC inhibitors. However
combination treatment of SAHA and ATRA or 9-cis RA increased
sub-G0/G1 DNA content to 22.37% and 23.36% respectively.
Moreover, SL142 and ATRA or 9-cis RA increased sub-G0/G1
DNA content to 32.82% and 56.92% and SL325 and ATRA or 9-
cis RA increased the content to 26.18% and 49.33% respectively
(Fig. 3B). The sub-G0/G1 DNA content induced by the single or
combination treatment in normal human lung fibroblast (NHLF)
was less than H441 cells (data not shown). Morphological analysis
showed that more cell death was induced after the combination
treatment of SL142 and ATRA or 9-cis RA than those of single use
(Fig. 3C). These results suggest that ATRA or 9-cis RA increase
caspase-3 activity and apoptosis induced by SAHA, SL142 or
SL325.
Effects of combination treatment of retinoic acids and
SL142 or SL325 on suppression of colony formation of
H441 lung cancer cells
To analyze the antitumor effect of the combination treatment of
ATRA or 9-cis RA and SL142 or SL325, a clonogenic assay was
performed. As shown in Fig. 4A and 4B, ATRA or 9-cis RA
weakly suppress colony formation of H441 lung cancer cells (69.1–
78.0%), while SAHA, SL142 or SL325 more strongly suppress
colony formation (40.2–69.4%). Significantly, ATRA or 9-cis RA
enhanced the anti-tumor effect of SAHA, SL142 or SL325
especially when combined with SL142 or SL325 and ATRA or 9-
cis RA drastically suppressed colony formation (2.52–13.22%).
These results suggest that the combination treatment of SL142 or
SL325 and ATRA or 9-cis RA synergically inhibits colony
formation of H441 lung cancer cells.
The combination treatment of SL142 or SL325 and ATRA
or 9-cis RA synergically increases the transcriptional
activity of RARE but does not alter expression of RAR and
RXR
To analyze the transcriptional activity of the retinoic acid
responsive element (RARE) after the treatment of SL142 or SL325
and ATRA or 9-cis RA, we generated a luciferase construct driven
by seven tandem repeats of the RARE element: pGL4. RARE 7x
[20,21]. pGL4. RARE 7x generated significant promoter activity
(5.26– to 17.11-fold) after administration of 2.5 mM ATRA or 9-cis
RA treatments in H441 lung cancer cells. However, the construct
showed little transcriptional activity after 0.5 mM of SAHA, SL142
or SL325 treatment in the cells (1.26– to 1.43- fold). Importantly,
SL142 and SL325 more significantly enhanced the promoter
activity of RARE after treatment of ATRA or 9-cis RA. (29.94– to
37.42-fold, 55.58– to 60.14-fold respectively) compared to SAHA
(14.99– to 24.65-fold) (Fig. 5A). However, as shown in Fig. 5B,
immuno blot analysis demonstrated that little change was seen in
the expression of RARa RARb, RXRa and RXRb expression
after the single or combination treatment in H441 lung cancer
cells.
The combination treatment with SL142 or SL325 and
ATRA or 9-cis RA increases Bax expression in H441 lung
cancer cells
In order to investigate the mechanism of the antitumor effect
induced by the combination treatment of ATRA or 9-cis RA and
SL142 or SL325, we analyzed the expression of p21, p27 and Bax
in H441 lung cancer cells. As shown in Fig. 6A, p21 expression
was significantly increased after SL142 treatment (Fig. 6A, lane 7–
9). After 9-cisRA, SAHA treatment or combination treatment with
SAHA and retinoids increased p27 expression (Fig. 6A, lane 1–6)
as reported by others [16], however no significant change was seen
in p27 expression after SL142 or SL325 treatment or the
combination treatment of SL142 or SL325 and retinoids
(Fig. 6A, lane 7–12). Importantly, Bax expression was increased
24 hours after SL142 or SL325 treatment (Fig. 6A, lane 7, 10) and
ATRA or 9-cis RA enhanced the expression (lane 8, 9, 11,12) in
H441 cells. The combination treatment of 9-cis RA and SL325
also increased Bax expression (lane 6). Next, we analyzed Bax
promoter activity after the combination treatment using the
luciferase construct containing the Bax promoter region: pGL4.
Bax. As shown in Fig. 6B, activation of the Bax promoter
remained (3.58– to 6.07-fold) after a single treatment of HDAC
inhibitors or retinoic acids in H441 lung cancer cells. Importantly,
SAHA enhanced Bax promoter activity induced by ATRA or 9-cis
RA (6.27– to 8.74-fold) and SL142 and SL325 enhanced even
more (10.14– to 18.44-fold). These results suggest that the
combination treatment of SL142 or SL325 and ATRA or 9-cis
RA can enhance the transcriptional activity of the Bax promoter
and induce Bax expression in H441 lung cancer cells.
Discussion
Lung cancer is the most common cause of cancer related deaths
worldwide [23]. Treatment of lung cancer with chemotherapy has
prolonged survival, however, clinical benefits with these agents is
restricted to patients in otherwise good health and those in early
stages. But all chemotherapy treatments also have undesirable side
effects for the patient [24]. Recently, small molecules have been
developed to treat lung cancer in patients carrying such mutated
genes as EGFR and EML4-ALK fusion genes. These small
molecules are designed to target the kinase domains of the mutated
genes and inhibit their activity [25,26]. However, such small
molecule therapy is not suitable for most lung cancer events,
including cancer caused by a mutated KRAS gene [27]. Clearly,
further investigation of newer, tolerated agents with novel
mechanisms of action is urgently needed in order to improve the
duration and quality of life for this large population of patients.
Nonselective inhibitors of human histone deacetylases (HDAC)
are reported to have antitumor activity in vivo, and several of them
are under clinical trials [9,28,29,30,31,32,33,34,35,36]. The first
of these, SAHA has been approved for treatment of cutaneous T-
cell lymphoma and it has also been reported that SAHA has an
Novel Therapy for Lung Cancer
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developed novel amide-bearing hydroxamic acid derivatives as
class-selective HDAC inhibitors termed SL142 and SL325
(Fig. 1A) and reported that these small molecules show more
significant HDAC1, HDAC4 and HDAC6 inhibitory activity in
human prostate cancer cells LNCaP than SAHA [17]. The half
maximal inhibitory concentrations (IC50s) of SL-142 against
HDAC1, HDAC4 and HDAC6 are 6965 nM, 5362 nM, and
260670 nM. The IC50s of SL-325 against HDAC1, HDAC4 and
HDAC6 are 12064 nM, 6564 nM, and 310650 nM. In contrast
the IC50s of the clinically used HDAC inhibitor suberoylanilide
hydroxamic acid ZolinzaTM against HDAC1 and HDAC4 are
much higher at 290650 nM, 340630 nM, and comparable to
HDAC6 at 200610 nM. Therefore, these compounds exhibit
more potent inhibitory activity on HDAC1 and HDAC4 and
comparable HDAC6 inhibitory activity as compared to the
Figure 3. Combination treatment of retinoic acids and SL142 or SL325 more significantly induced cell death in H441 lung cancer
cells than those of single use. A. Analysis of caspase-3 activity induced by ATRA or 9-cis RA (2.5 mM) and/or SAHA, SL142 or SL325 (0.5 mM) in
H441 lung cancer cells. Cells were treated with SAHA, SL142 or SL325 at the concentration of 2.5 mM for 36 hours. After 36 hours of treatment, sub-
G0/G1 DNA content was measured by propidium iodide staining and flow cytometric analysis. Triplicate experiments were performed; data represent
the mean-fold increase 6 S.E. *, significant difference from control cells (cells without treatments) (p,0.05). B. Flow cytometric analysis of apoptosis
induced by ATRA or 9-cis RA (2.5 mM) and/or SAHA, SL142 or SL325 (0.5 mM) in H441 lung cancer cells. After 96 hours of treatment, sub-G0/G1 DNA
content was measured by propidium iodide staining and flow cytometric analysis. C. Morphological analysis of H441 cells after ATRA or 9-cis RA
(2.5 mM) and/or SL142 (0.5 mM) treatment.
doi:10.1371/journal.pone.0013834.g003
Figure 4. Combination effects of ATRA or 9-cis RA and SAHA, SL142 or SL325 on suppression of colony formation in H441 lung
cancer cells. A. Colony formation of H441 cells treated with ATRA or 9-cis RA (2.5 mM) or/and SAHA, SL142 or SL325 (0.5 mM) for 36 hours. The assay
was initiated by plating 2610
3 cells per 100-mm dishes. After 16 days, cells were fixed and stained with crystal violet. Representative pictures of
experiments performed in triplicate are shown. B. Mean colony numbers were derived from quantitation of triplicate dishes for each treatment and
percentage-specific cytotoxicity compared to colony formation in the DMSO group (control) was calculated. *, p,0.05 versus single agents.
doi:10.1371/journal.pone.0013834.g004
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(ZolinzaTM) [18,19].
In the present study, SL142 and SL325 showed more significant
HADC inhibitory activity (HAT activity) in H441 lung cancer cells
(Fig. 1B) and suppressed tumor viability in H441 and A549 lung
cancer cells than SAHA (Fig. 1C), indicating that SL142 and
SL325 are more effective HDAC inhibitors than SAHA. In our
previous report, SL142 and SL325 showed significant p21
promoter activity and cytostatic activity in prostate cancer cells
LNCaP [17]. However, in this study, these small molecules also
induced significant caspase-3 activity and subG0/G1 population in
H441 and A549 lung cancer cells. These results suggest that
SL142 and SL325 could induce apoptosis in lung cancer.
Retinoic acids modulate normal, premalignant, and malignant
cell phenotypes by changes in gene expression that are mediated
through binding to two classes of nuclear hormone receptors, the
RARs and the RXRs. ATRA binds RAR with high affinity but
does not bind to RXR, whereas 9-cis RA is a ligand that binds and
transactivates both RARs and RXRs [39,40]. Retinoic acids
regulate differentiation in airway epithelium and suppress
carcinogenesis for lung cancer and head and neck cancer
[41,42,43]. Importantly, it has been reported that the combination
treatment of HDAC inhibitors and retinoic acids increased anti-
tumor activity in malignant cells [44,45,46,47]. Furthermore,
Epping et al. reported that the retinoic acid receptor (RAR)
pathway is targeted by HDAC inhibitor and that the antitumor
Figure 5. The combination treatment of retinoic acids and/or SL142 or SL325 synergically increased the transcriptional activity of
RARE in H441 lung cancer cells. A. Transient transfection reporter assays in H441 cells with pGL4. or pGL4.RARE 7x (2 mg), plus pCMV. b-
galactosidase (2 mg) after retinoic acids (2.5 mM) and/or SL142 or SL325 (0.5 mM) retinoic acids treatment. Results are presented as fold induction of
relative light units normalized to b-galactosidase activity relative to that observed for control constructs.
#, significant difference from the promoter
activity generated by pGL4.RARE 7x after ATRA and SAHA treatment (p,0.05). *, significant difference from the promoter activity generated by
pGL4.RARE 7x after 9-cis RA and SAHA treated cells (p,0.05). B. Immunoblot analysis of RARa, RARb, RXRa and RXRb expressions after retinoic acids
and/or SL142 or SL325 treatment in H441 lung cancer cells. Human lung cancer cells were harvested 24 hours after treatment with ATRA or 9-cis RA
(2.5 mM) or/and SAHA, SL142 or SL325 (0.5 mM). b-actin is shown as control.
doi:10.1371/journal.pone.0013834.g005
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derepression of retinoic acid [48]. In our study, the combination
treatment of SL142 or SL325 with these retinoic acids synergically
increased apoptosis and suppressed colony formation in the cells
(Fig. 3A, 3B, 4A and 4B). Moreover, transcriptional activity
generated by RARE after the combination treatment was much
higher than that of a single treatment (Fig. 5A). RAR is known to
form a heterodimer with RXR and binds to a retinoic acid
responsive element (RARE) [49,50]. However, expression of these
receptors was not increased after the treatment in H441 lung
cancer cells (Fig. 5B)[45,51]. Both retinoic acids and HDAC
inhibitors have been reported to activate cell cycle or apoptosis
related genes and induce cell differentiation or apoptosis in cancer
cells [52,53,54,55,56,57,58,59,60,61]. In our report, expression of
p21 was clearly increased after SL142 treatment in H441 lung
cancer cells and more importantly, Bax expression was increased
after the combination treatment of HDAC inhibitors and retinoic
acids. Expression of p27 was not changed after SL142 or SL325
and/or retinoid treatment[16]. The promoter of the p21 gene
contains a functional RARE [62] and this is consistent with our
results (Fig. 5A). However, p21 was originally identified as a
molecule that regulates the transition from the G1 phase to the S
phase of the cell cycle and overexpression of p21 has been shown
to induce differentiation in various cells rather than induce
caspase-3 activity and apoptosis [63,64,65,66]. On the other hand
over expression of Bax induces caspase-3 activity and apoptosis in
many kinds of cells [67,68,69]. In this study the combination
treatment of SL325 and retinoic acids significantly induced cell
Figure 6. The combination treatment of retinoic acids and/or SL142 or SL325 increased Bax protein expression and the promoter
activity in H441 lung cancer cells. A. Immunoblot analysis of RARa, RARb, RXRa and RXRb expressions after retinoic acids and/or SL142 or SL325
treatment in H441 lung cancer cells. Human lung cancer cells were harvested 24 hours after treatment with ATRA or 9-cis RA (2.5 mM) or/and SAHA,
SL142 or SL325 (0.5 mM). b-actin is shown as control. B. Transient transfection reporter assays in H441 cells with pGL4. or pGL4.Bax (2 mg), plus pCMV.
b-galactosidase (2 mg) after retinoic acids (2.5 mM) and/or SL142 or SL325 (0.5 mM) retinoic acids treatment. Results are indicated as Fig. 6A.
*, significant difference from the promoter activity generated by pGL4.Bax after ATRA or 9-cis RA (2.5 mM) or SAHA, SL142 or SL325 (0.5 mM) (p,0.05).
doi:10.1371/journal.pone.0013834.g006
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treatment hardly increased p21 expression (Fig. 6A). As shown in
Fig. 6A, p53 expression was not altered after the treatment and
H441 non-small lung cancer cells carry mutated p53. These results
suggest that up regulation of Bax may have a crucial role in the
antitumor effect of the combination treatment of SL142 or SL325
and ATRA or 9-cis RA in H441 lung cancer cells [54] and Bax
was up regulated in p53 independent pathway. As shown in
Fig. 6A, p53 expression was not altered after the treatment and
H441 non-small lung cancer cells carry mutated p53. On the other
hand, as shown in Fig. 1C and Fig. 2A, H1299 non-small cell lung
cancer cells were less sensitive to SL142 and SL325 compared to
H441 and A549 cells and the combination effect was not seen in
the cells. For example, H441 and A549 have KRas mutations
while H1299 does not. However, we do not know yet which
genetic types of NSCLC are responsive to this combination
therapy [70,71]. Further investigation is needed to determine
which kinds of lung cancer can be targeted by the combination
treatment of SL142 or SL325 and retinoids. We are thus planning
to study the applicability of combination therapy using a larger
number of cell lines. However, the present study suggests that the
combination of retinoic acids and these new kinds of HDAC
inhibitors might be a promising approach for treating lung cancer.
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